{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:27:05Z","timestamp":1793327225330,"version":"4.5.0"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015640","name":"Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology","doi-asserted-by":"publisher","award":["2024B11"],"award-info":[{"award-number":["2024B11"]}],"id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.diabres.2025.112204","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T14:35:48Z","timestamp":1745678148000},"page":"112204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Metabolic crosstalk and therapeutic interplay between diabetes and hyperuricemia"],"prefix":"10.1016","volume":"224","author":[{"given":"Tianshu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9711","key":"10.1016\/j.diabres.2025.112204_b0005","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"Richette","year":"2010","journal-title":"Gout Lancet"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12902-023-01408-0","article-title":"Prevalence of hyperuricemia among type 2 diabetes mellitus patients in Africa: a systematic review and meta-analysis","volume":"23","author":"Alemayehu","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.diabres.2025.112204_b0015","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.2147\/DMSO.S252825","article-title":"Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients attending Jimma Medical Center, Southwestern Ethiopia, 2019","volume":"13","author":"Arersa","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0020","first-page":"590","article-title":"Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients with central obesity in Guangdong Province in China","volume":"22","author":"Wang","year":"2013","journal-title":"Asia Pac J Clin Nutr"},{"issue":"11","key":"10.1016\/j.diabres.2025.112204_b0025","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1210\/jc.2015-2527","article-title":"Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies","volume":"100","author":"Yuan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11892-023-01506-2","article-title":"Prevalence of diabetes in patients with hyperuricemia and gout: a systematic review and meta-analysis","volume":"23","author":"Jiang","year":"2023","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.diabres.2025.112204_b0035","article-title":"Change of serum uric acid and progression of cardiometabolic multimorbidity among middle aged and older adults: a prospective cohort study","volume":"10","author":"Li","year":"2022","journal-title":"Front Public Health"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0040","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.2337\/dc18-2147","volume":"42","author":"Bjornstad","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-020-00672-8","article-title":"Association between decreased thyroid stimulating hormone and hyperuricemia in type 2 diabetic patients with early-stage diabetic kidney disease","volume":"21","author":"Feng","year":"2021","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0050","doi-asserted-by":"crossref","first-page":"12968","DOI":"10.1038\/s41598-024-63340-0","article-title":"Association between uric acid and referable diabetic retinopathy in patients with type 2 diabetes","volume":"14","author":"Rivera-De-la-Parra","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12886-017-0486-3","article-title":"Correlation of retinal nerve fibre layer and macular thickness with serum uric acid among type 2 diabetes mellitus","volume":"17","author":"Vinuthinee-Naidu","year":"2017","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1167\/iovs.62.4.23","article-title":"Higher serum uric acid levels are associated with an increased risk of vision-threatening diabetic retinopathy in type 2 diabetes patients","volume":"62","author":"Hu","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0065","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.diabres.2014.07.027","article-title":"Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan\u2013a 3-year prospective study","volume":"106","author":"Lee","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2025.112204_b0070","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.2147\/RMHP.S255042","article-title":"Study on the risk factors for hyperuricaemia and related vascular complications in patients with type 2 diabetes mellitus","volume":"13","author":"Shi","year":"2020","journal-title":"Risk Manag Healthc Policy"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0075","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and gout reduction bySGLT2 inhibitors in diabetes and heartfailure: JACCreview topic of the week","volume":"83","author":"Packer","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"14","key":"10.1016\/j.diabres.2025.112204_b0085","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1111\/jcmm.16677","article-title":"Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo","volume":"25","author":"Jiao","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"9","key":"10.1016\/j.diabres.2025.112204_b0090","doi-asserted-by":"crossref","first-page":"F993","DOI":"10.1152\/ajprenal.00637.2014","article-title":"Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy","volume":"308","author":"Kim","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"15","key":"10.1016\/j.diabres.2025.112204_b0095","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.1111\/jcmm.15523","article-title":"Soluble uric acid induces myocardial damage through activating the NLRP3 inflammasome","volume":"24","author":"Zhang","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0100","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1186\/s12967-024-05778-4","article-title":"Hyperuricemia suppresses lumican, exacerbating adverse remodeling after myocardial infarction by promoting fibroblast phenotype transition","volume":"22","author":"Zhuang","year":"2024","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.bbrc.2018.06.097","article-title":"The role of uric acid in the pathogenesis of diabetic retinopathy based on Notch pathway","volume":"503","author":"Zhu","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.diabres.2025.112204_b0110","doi-asserted-by":"crossref","first-page":"10868","DOI":"10.1002\/jcp.27929","article-title":"Uric acid and angiotensin II additively promote inflammation and oxidative stress in human proximal tubule cells by activation of toll-like receptor 4","volume":"234","author":"Milanesi","year":"2019","journal-title":"J Cell Physiol"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/cen.12673","article-title":"Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study","volume":"83","author":"Liu","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.diabres.2025.112204_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106407","article-title":"Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?","volume":"184","author":"Polito","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabres.2025.112204_b0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cca.2018.05.046","article-title":"Uric acid and cardiovascular disease","volume":"484","author":"Ndrepepa","year":"2018","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.diabres.2025.112204_b0130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jconrel.2023.09.011","article-title":"Gout therapeutics and drug delivery","volume":"362","author":"Peng","year":"2023","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0135","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41584-018-0149-7","article-title":"Prevention and treatment of gout","volume":"15","author":"Stamp","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-024-00542-w","article-title":"Tumour lysis syndrome","volume":"10","author":"Howard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.diabres.2025.112204_b0145","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0150","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/art.42009","article-title":"Association Between Gut Microbiota and Elevated Serum Urate in Two Independent Cohorts","volume":"74","author":"Wei","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.diabres.2025.112204_b0155","article-title":"The Gut Microbiome in Hyperuricemia and Gout. Arthritis","author":"Terkeltaub","year":"2025","journal-title":"Rheumatol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Gout Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0165","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.kint.2024.05.033","article-title":"Controversies and practical management of patients with gout and chronic kidney disease","volume":"106","author":"Johnson","year":"2024","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.diabres.2025.112204_b0170","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tem.2017.03.003","article-title":"Unraveling the Regulation of Hepatic Metabolism by Insulin","volume":"28","author":"Titchenell","year":"2017","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0175","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","article-title":"Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism","volume":"64","author":"Wan","year":"2016","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0180","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2014.04.080","article-title":"High uric acid directly inhibits insulin signalling and induces insulin resistance","volume":"447","author":"Zhu","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.diabres.2025.112204_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101411","article-title":"URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice","volume":"55","author":"Tanaka","year":"2022","journal-title":"Mol Metab"},{"issue":"12","key":"10.1016\/j.diabres.2025.112204_b0190","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1042\/CS20200580","article-title":"Metformin alleviates hyperuricaemia-induced serum FFA elevation and insulin resistance by inhibiting adipocyte hypertrophy and reversing suppressed white adipose tissue beiging","volume":"134","author":"Su","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.diabres.2025.112204_b0195","article-title":"RBP4 Is Associated With Insulin Resistance in Hyperuricemia-Induced Rats and Patients With Hyperuricemia","volume":"12","author":"Liu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147737","article-title":"High Uric Acid Induces Insulin Resistance in Cardiomyocytes In Vitro and In Vivo","volume":"11","author":"Zhi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.diabres.2025.112204_b0205","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.mce.2016.12.025","article-title":"Metformin ameliorates high uric acid-induced insulin resistance in skeletal muscle cells","volume":"443","author":"Yuan","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.diabres.2025.112204_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.111070","article-title":"High uric acid promotes dysfunction in pancreatic beta cells by blocking IRS2\/AKT signalling","volume":"520","author":"Hu","year":"2021","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0215","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2337\/db19-0704","article-title":"Hyperuricemia predisposes to the onset of diabetes via promoting pancreatic beta-cell death in uricase-deficient male mice","volume":"69","author":"Lu","year":"2020","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0220","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7555\/JBR.28.20130170","article-title":"Luteolin prevents uric acid-induced pancreatic beta-cell dysfunction","volume":"28","author":"Ding","year":"2014","journal-title":"J Biomed Res"},{"issue":"1\u20132","key":"10.1016\/j.diabres.2025.112204_b0225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.mce.2013.04.027","article-title":"Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic beta cells","volume":"375","author":"Zhang","year":"2013","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0230","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.bmcl.2004.12.003","article-title":"Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells","volume":"15","author":"Rocic","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"10.1016\/j.diabres.2025.112204_b0235","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2337\/dc09-0288","article-title":"Association between serum uric acid and development of type 2 diabetes","volume":"32","author":"Kodama","year":"2009","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2025.112204_b0240","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41574-019-0254-y","article-title":"The heterogeneous pathogenesis of type 1 diabetes mellitus","volume":"15","author":"Ilonen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.diabres.2025.112204_b0245","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1043-2760(00)00324-6","article-title":"Transplantation of the islets of Langerhans: new hope for treatment of type 1 diabetes mellitus","volume":"11","author":"Liu","year":"2000","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.diabres.2025.112204_b0250","doi-asserted-by":"crossref","DOI":"10.1111\/exd.70090","article-title":"Hyperuricemia exacerbates psoriatic inflammation by inducing M1 macrophage activation and Th1 cell differentiation","volume":"34","author":"Wei","year":"2025","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0255","doi-asserted-by":"crossref","first-page":"12537","DOI":"10.1038\/s41598-023-39775-2","article-title":"Hyperuricemia is accompanied by elevated peripheral CD4(+) T cells","volume":"13","author":"Yu","year":"2023","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2025.112204_b0260","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.diabres.2008.09.018","article-title":"Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy","volume":"82","author":"Rosolowsky","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.diabres.2025.112204_b0265","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","article-title":"Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence","volume":"17","author":"Tan","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0270","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13098-023-01182-y","article-title":"Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"15","author":"You","year":"2023","journal-title":"Diabetol Metab Syndr"},{"issue":"11","key":"10.1016\/j.diabres.2025.112204_b0275","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2215\/CJN.03140315","article-title":"Serum Uric Acid and Risk of CKD in Type 2 Diabetes","volume":"10","author":"De Cosmo","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.diabres.2025.112204_b0280","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.numecd.2021.06.012","article-title":"Association of serum uric acid with biventricular myocardial dysfunction in patients with type 2 diabetes mellitus","volume":"31","author":"Liu","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"12","key":"10.1016\/j.diabres.2025.112204_b0285","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.25122\/jml-2022-0068","article-title":"The effect of serum uric acid concentration on the severity of chronic congestive heart failure","volume":"15","author":"Alshamari","year":"2022","journal-title":"J Med Life"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0290","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijcard.2010.05.002","article-title":"Hyperuricemia predicts adverse outcomes in patients with heart failure","volume":"151","author":"Hamaguchi","year":"2011","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0295","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2337\/dc22-1339","article-title":"Association of serum uric acid with all-cause and cardiovascular mortality in diabetes","volume":"46","author":"Li","year":"2023","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0300","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s42255-023-00783-1","article-title":"Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction","volume":"5","author":"Monzel","year":"2023","journal-title":"Nat Metab"},{"key":"10.1016\/j.diabres.2025.112204_b0305","article-title":"L-carnitine attenuated hyperuricemia-associated left ventricular remodeling through ameliorating cardiomyocytic lipid deposition","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"16\u201318","key":"10.1016\/j.diabres.2025.112204_b0310","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1089\/ars.2023.0473","article-title":"High uric acid orchestrates ferroptosis to promote cardiomyopathy via ROS-GPX4 signaling","volume":"41","author":"Xu","year":"2024","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"10.1016\/j.diabres.2025.112204_b0315","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1159\/000488048","article-title":"Uric acid induces cardiomyocyte apoptosis via activation of calpain-1 and endoplasmic reticulum stress","volume":"45","author":"Yan","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0320","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijcard.2008.09.004","article-title":"Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts","volume":"139","author":"Cheng","year":"2010","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.diabres.2025.112204_b0325","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202300393R","article-title":"Hyperuricemia: A key contributor to endothelial dysfunction in cardiovascular diseases","volume":"37","author":"Wei","year":"2023","journal-title":"Faseb j"},{"issue":"3","key":"10.1016\/j.diabres.2025.112204_b0330","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jjcc.2012.01.013","article-title":"Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications","volume":"59","author":"Puddu","year":"2012","journal-title":"J Cardiol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-018-0042-6","article-title":"Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy","volume":"40","author":"Knapp","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.diabres.2025.112204_b0340","article-title":"Endothelial Dysfunction and Diabetic Cardiomyopathy","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabres.2025.112204_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114252","article-title":"Diabetic nephropathy: focusing on pathological signals, clinical treatment, and dietary regulation","volume":"159","author":"Hu","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0350","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165654","article-title":"Molecular pathways that drive diabetic kidney disease","volume":"133","author":"Mohandes","year":"2023","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0355","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.diabet.2019.03.001","article-title":"Coexistence of hyper-uricaemia and low urinary uric acid excretion further increases risk of chronic kidney disease in type 2 diabetes","volume":"45","author":"Chen","year":"2019","journal-title":"Diabetes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0360","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/dmrr.2768","article-title":"Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study","volume":"32","author":"Chang","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"issue":"8","key":"10.1016\/j.diabres.2025.112204_b0365","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/ndt\/gfy138","article-title":"Effects of uric acid on kidney function decline differ depending on baseline kidney function in type 2 diabetic patients","volume":"34","author":"Hanai","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabres.2025.112204_b0370","article-title":"Uric acid and impairment of renal function in non-diabetic hypertensive patients","volume":"8","author":"Hung","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10.1016\/j.diabres.2025.112204_b0375","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1007\/s11255-024-04094-6","article-title":"Association between hyperuricemia and diabetic nephropathy: insights from the national health and nutrition examination survey 2007-2016 and mendelian randomization analysis","volume":"56","author":"Wu","year":"2024","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129797","article-title":"Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population","volume":"10","author":"Yan","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.diabres.2025.112204_b0385","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jdiacomp.2016.06.002","article-title":"Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus","volume":"30","author":"Bart\u00e1kov\u00e1","year":"2016","journal-title":"J Diabetes Complications"},{"issue":"8","key":"10.1016\/j.diabres.2025.112204_b0390","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jdiacomp.2015.08.016","article-title":"Gender differences in the association between hyperuricemia and diabetic kidney disease in community elderly patients","volume":"29","author":"Guo","year":"2015","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2025.112204_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108005","article-title":"Different associations between serum urate and diabetic complications in men and postmenopausal women","volume":"160","author":"Wan","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.diabres.2025.112204_b0400","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s11010-020-03997-z","article-title":"The roles of NLRP3 inflammasome-mediated signaling pathways in hyperuricemic nephropathy","volume":"476","author":"Wen","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.diabres.2025.112204_b0405","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.phrs.2016.11.004","article-title":"Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy","volume":"114","author":"Qiu","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabres.2025.112204_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102108","article-title":"Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine\/dimethylarginine dimethylaminotransferase 2 pathway","volume":"46","author":"Lee","year":"2021","journal-title":"Redox Biol"},{"issue":"3","key":"10.1016\/j.diabres.2025.112204_b0415","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.kint.2024.10.025","article-title":"Activating soluble guanylyl cyclase attenuates ischemic kidney damage","volume":"107","author":"Lichtenberger","year":"2025","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0420","doi-asserted-by":"crossref","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","article-title":"Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism","volume":"282","author":"Mazzali","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0425","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1080\/13880209.2023.2243086","article-title":"Clerodendranthus spicatus inhibits epithelial-mesenchymal transition of renal tubular cells through the NF-\u03baB\/Snail signalling pathway in hyperuricaemia nephropathy","volume":"61","author":"Wu","year":"2023","journal-title":"Pharm Biol"},{"issue":"12","key":"10.1016\/j.diabres.2025.112204_b0430","doi-asserted-by":"crossref","first-page":"13334","DOI":"10.1096\/fj.201901148R","article-title":"Uric acid induced the phenotype transition of vascular endothelial cells via induction of oxidative stress and glycocalyx shedding","volume":"33","author":"Ko","year":"2019","journal-title":"Faseb j"},{"issue":"5","key":"10.1016\/j.diabres.2025.112204_b0435","doi-asserted-by":"crossref","first-page":"F471","DOI":"10.1152\/ajprenal.00560.2012","article-title":"Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease","volume":"304","author":"Ryu","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0440","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jmii.2017.12.004","article-title":"Monosodium urate crystals induced ICAM-1 expression and cell-cell adhesion in renal mesangial cells: implications for the pathogenesis of gouty nephropathy","volume":"53","author":"Luo","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0445","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10495-014-1057-1","article-title":"Oxidative stress by monosodium urate crystals promotes renal cell apoptosis through mitochondrial caspase-dependent pathway in human embryonic kidney 293 cells: mechanism for urate-induced nephropathy","volume":"20","author":"Choe","year":"2015","journal-title":"Apoptosis"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0450","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-8587(19)30411-5","article-title":"Screening for diabetic retinopathy: new perspectives and challenges","volume":"8","author":"Vujosevic","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0455","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/JCMA.0000000000000285","article-title":"Serum uric acid is independently associated with diabetic nephropathy but not diabetic retinopathy in patients with type 2 diabetes mellitus","volume":"83","author":"Xia","year":"2020","journal-title":"J Chin Med Assoc"},{"issue":"5","key":"10.1016\/j.diabres.2025.112204_b0460","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.2337\/db18-0912","article-title":"Monosodium urate contributes to retinal inflammation and progression of diabetic retinopathy","volume":"68","author":"Thounaojam","year":"2019","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0465","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.exer.2010.11.007","article-title":"Involvement of oxidative stress and mitochondrial dysfunction in the osmotic swelling of retinal glial cells from diabetic rats","volume":"92","author":"Kr\u00fcgel","year":"2011","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0470","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/10799893.2017.1369120","article-title":"Prorenin receptor (PRR)-mediated NADPH oxidase (Nox) signaling regulates VEGF synthesis under hyperglycemic condition in ARPE-19 cells","volume":"37","author":"Haque","year":"2017","journal-title":"J Recept Signal Transduct Res"},{"key":"10.1016\/j.diabres.2025.112204_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100954","article-title":"VEGFR1 signaling in retinal angiogenesis and microinflammation","volume":"84","author":"Uemura","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0480","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/rheumatology\/keaa668","article-title":"The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study","volume":"60","author":"Xue","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.diabres.2025.112204_b0485","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/1389557523666230913091558","article-title":"Recent Advances in Xanthine Oxidase Inhibitors","volume":"24","author":"Sun","year":"2024","journal-title":"Mini Rev Med Chem"},{"issue":"26","key":"10.1016\/j.diabres.2025.112204_b0490","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of Allopurinol on the Progression of Chronic Kidney Disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0495","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","article-title":"Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial","volume":"65","author":"Goicoechea","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.diabres.2025.112204_b0500","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13757","article-title":"Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: a systematic review and meta-analysis","volume":"17","author":"Deng","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0505","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000573","article-title":"The role of febuxostat in gout","volume":"31","author":"Bardin","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.diabres.2025.112204_b0510","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/13543784.2018.1471133","article-title":"Investigational drugs for hyperuricemia, an update on recent developments","volume":"27","author":"Pascart","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"22","key":"10.1016\/j.diabres.2025.112204_b0515","doi-asserted-by":"crossref","first-page":"19966","DOI":"10.1021\/acs.jmedchem.4c01260","article-title":"Recent progress and future perspectives on anti-hyperuricemic agents","volume":"67","author":"Sun","year":"2024","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0520","first-page":"374","article-title":"Lesinurad (Zurampic) for Gout","volume":"97","author":"On","year":"2018","journal-title":"Am Fam Physician"},{"issue":"11","key":"10.1016\/j.diabres.2025.112204_b0525","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/14656566.2021.1918102","article-title":"Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout","volume":"22","author":"Ishikawa","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.diabres.2025.112204_b0530","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1681\/ASN.0000000000000326","article-title":"Combination treatment with verinurad and allopurinol in CKD: a randomized placebo and active controlled trial","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.diabres.2025.112204_b0535","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/dmrr.2295","article-title":"Allopurinol attenuates left ventricular dysfunction in rats with early stages of streptozotocin-induced diabetes","volume":"28","author":"Gao","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"10.1016\/j.diabres.2025.112204_b0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067009","article-title":"Multiple antioxidants improve cardiac complications and inhibit cardiac cell death in streptozotocin-induced diabetic rats","volume":"8","author":"Kumar","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.diabres.2025.112204_b0545","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008807","article-title":"Xanthine oxidase inhibitor allopurinol prevents oxidative stress-mediated atrial remodeling in alloxan-induced diabetes mellitus rabbits","volume":"7","author":"Yang","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"8b","key":"10.1016\/j.diabres.2025.112204_b0550","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1111\/j.1582-4934.2008.00564.x","article-title":"Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy","volume":"13","author":"Rajesh","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.diabres.2025.112204_b0555","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2021.11.076","article-title":"Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease","volume":"349","author":"Konishi","year":"2022","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0560","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxsci\/kfac073","article-title":"Febuxostat increases ventricular arrhythmogenesis through calcium handling dysregulation in human-induced pluripotent stem cell-derived cardiomyocytes","volume":"189","author":"Zhu","year":"2022","journal-title":"Toxicol Sci"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0565","article-title":"Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0570","first-page":"128","article-title":"Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients","volume":"4","author":"Momeni","year":"2010","journal-title":"Iran J Kidney Dis"},{"issue":"12","key":"10.1016\/j.diabres.2025.112204_b0575","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.14740\/jocmr3219w","article-title":"Urate-lowering therapy ameliorates kidney function in type 2 diabetes patients with hyperuricemia","volume":"9","author":"Ueno","year":"2017","journal-title":"J Clin Med Res"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218510","article-title":"Urate-lowering agents for asymptomatic hyperuricemia in stage 3\u20134 chronic kidney disease: Controversial role of kidney function","volume":"14","author":"Jeon","year":"2019","journal-title":"PLoS One"},{"issue":"26","key":"10.1016\/j.diabres.2025.112204_b0585","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.diabres.2025.112204_b0590","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194680","article-title":"Xanthine oxidase inhibitor febuxostat exerts an anti-inflammatory action and protects against diabetic nephropathy development in KK-Ay obese diabetic mice","volume":"20","author":"Mizuno","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0595","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000363421","article-title":"Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model","volume":"40","author":"Lee","year":"2014","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0600","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043807","article-title":"Inhibition of xanthine oxidase protects against diabetic kidney disease through the amelioration of oxidative stress via VEGF\/VEGFR Axis and NOX-FoxO3a-eNOS signaling pathway","volume":"24","author":"Yang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.diabres.2025.112204_b0605","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1111\/bph.13527","article-title":"Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes","volume":"173","author":"Komers","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.diabres.2025.112204_b0610","first-page":"563","article-title":"Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: a 6-months open-label, randomized controlled trial","volume":"17","author":"Mukri","year":"2018","journal-title":"Excli j"},{"issue":"7","key":"10.1016\/j.diabres.2025.112204_b0615","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2337\/db17-0168","article-title":"Renal and vascular effects of uric acid lowering in normouricemic patients with uncomplicated type 1 diabetes","volume":"66","author":"Lytvyn","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2025.112204_b0620","doi-asserted-by":"crossref","DOI":"10.1177\/2054358116675343","article-title":"A randomized controlled trial of the effects of febuxostat therapy on adipokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy","volume":"3","author":"Beddhu","year":"2016","journal-title":"Can J Kidney Health Dis"},{"issue":"22","key":"10.1016\/j.diabres.2025.112204_b0625","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2169\/internalmedicine.55.6791","article-title":"Comparison of the renoprotective effect of febuxostat for the treatment of hyperuricemia between patients with and without type 2 diabetes mellitus: a retrospective observational study","volume":"55","author":"Ito","year":"2016","journal-title":"Intern Med"},{"key":"10.1016\/j.diabres.2025.112204_b0630","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejphar.2016.03.055","article-title":"Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db\/db mice","volume":"780","author":"Nakamura","year":"2016","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.diabres.2025.112204_b0635","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/nep.13177","article-title":"Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): a prospective, randomized, multicentre clinical trial","volume":"23","author":"Mizukoshi","year":"2018","journal-title":"Nephrology (Carlton)"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0640","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10157-018-1530-1","article-title":"Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study)","volume":"22","author":"Wada","year":"2018","journal-title":"Clin Exp Nephrol"},{"issue":"12","key":"10.1016\/j.diabres.2025.112204_b0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100911","article-title":"Pegloticase-induced rapid uric acid lowering and kidney and cardiac health markers in youth-onset type 2 diabetes: a pilot clinical trial","volume":"6","author":"Narongkiatikhun","year":"2024","journal-title":"Kidney Med"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0650","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020567","article-title":"Urate transporter 1 can be a therapeutic target molecule for chronic kidney disease and diabetic kidney disease: a retrospective longitudinal study","volume":"11","author":"Yanai","year":"2023","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.diabres.2025.112204_b0655","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4103\/1735-5362.213985","article-title":"Can allopurinol improve retinopathy in diabetic rats? Oxidative stress or uric acid; which one is the culprit?","volume":"12","author":"Goharinia","year":"2017","journal-title":"Res Pharm Sci"},{"issue":"10","key":"10.1016\/j.diabres.2025.112204_b0660","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/iovs.63.10.8","article-title":"Short-term hyperuricemia leads to structural retinal changes that can be reversed by serum uric acid lowering agents in mice","volume":"63","author":"Pai","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.diabres.2025.112204_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118290","article-title":"Xanthine oxidase inhibitor allopurinol improves atrial electrical remodeling in diabetic rats by inhibiting CaMKII\/NCX signaling","volume":"259","author":"Yang","year":"2020","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0670","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40264-024-01485-7","article-title":"Drug-induced hypouricemia","volume":"48","author":"Ben Salem","year":"2025","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101501","article-title":"Allopurinol hypersensitivity: Pathogenesis and prevention","volume":"34","author":"Stamp","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.diabres.2025.112204_b0680","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.839154","article-title":"Allopurinol-induced stevens-johnson syndrome in Javanese Men With Positive HLA-B*58:01","volume":"13","author":"Ferdiana","year":"2022","journal-title":"Front Genet"},{"issue":"3","key":"10.1016\/j.diabres.2025.112204_b0685","doi-asserted-by":"crossref","first-page":"E94","DOI":"10.1503\/cmaj.201022","article-title":"Azathioprine-induced severe anemia potentiated by the concurrent use of allopurinol","volume":"193","author":"Madrazo","year":"2021","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0690","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ng.2500","article-title":"Genome-wide association analyses identify 18 new loci associated with serum urate concentrations","volume":"45","author":"K\u00f6ttgen","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0695","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/dom.15310","article-title":"The effect of metformin on urate metabolism: findings from observational and Mendelian randomization analyses","volume":"26","author":"Dai","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112204_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120543","article-title":"Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: a mechanism review","volume":"300","author":"Lingli","year":"2022","journal-title":"Life Sci"},{"issue":"7","key":"10.1016\/j.diabres.2025.112204_b0705","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.diabres.2025.112204_b0710","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ejhf.2972","article-title":"Foetal recapitulation of nutrient surplus signalling by O-GlcNAcylation and the failing heart","volume":"25","author":"Packer","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.diabres.2025.112204_b0715","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1681\/ASN.0000000000000177","article-title":"Fetal Reprogramming of Nutrient Surplus Signaling, O-GlcNAcylation, and the Evolution of CKD","volume":"34","author":"Packer","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0720","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"41","key":"10.1016\/j.diabres.2025.112204_b0725","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1021\/bi500582r","article-title":"Measurement and characterization of superoxide generation from xanthine dehydrogenase: a redox-regulated pathway of radical generation in ischemic tissues","volume":"53","author":"Lee","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.diabres.2025.112204_b0730","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.metabol.2017.01.031","article-title":"Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans","volume":"70","author":"Washio","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2025.112204_b0735","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2016.11.077","article-title":"Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure","volume":"228","author":"Otaki","year":"2017","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.diabres.2025.112204_b0740","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0745","doi-asserted-by":"crossref","first-page":"F527","DOI":"10.1152\/ajprenal.00134.2012","article-title":"Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses","volume":"303","author":"Witkowska","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0750","doi-asserted-by":"crossref","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1","volume":"316","author":"Novikov","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"10.1016\/j.diabres.2025.112204_b0755","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7150\/ijbs.33007","article-title":"Empagliflozin attenuates hyperuricemia by upregulation of ABCG2 via AMPK\/AKT\/CREB signaling pathway in type 2 diabetic mice","volume":"16","author":"Lu","year":"2020","journal-title":"Int J Biol Sci"},{"issue":"3","key":"10.1016\/j.diabres.2025.112204_b0760","doi-asserted-by":"crossref","first-page":"F826","DOI":"10.1152\/ajprenal.00012.2017","article-title":"Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2","volume":"313","author":"Toyoki","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0765","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1159\/000495814","article-title":"Alterations of renal epithelial glucose and uric acid transporters in fructose induced metabolic syndrome","volume":"43","author":"Ng","year":"2018","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"10.1016\/j.diabres.2025.112204_b0770","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2025.112204_b0775","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/M19-2610","article-title":"Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.diabres.2025.112204_b0780","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.jchf.2024.08.020","article-title":"Uric acid and SGLT2 inhibition with empagliflozin in heartfailure with preserved ejection fraction: the EMPEROR-preserved trial","volume":"12","author":"Doehner","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"36","key":"10.1016\/j.diabres.2025.112204_b0785","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0790","first-page":"26","article-title":"Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression","volume":"72","author":"Ghukasyan","year":"2025","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"12","key":"10.1016\/j.diabres.2025.112204_b0795","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s12325-015-0272-7","article-title":"Management of chronic kidney disease: the relationship between serum uric acid and development of nephropathy","volume":"32","author":"Mende","year":"2015","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.diabres.2025.112204_b0800","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ndt\/gfae203","article-title":"Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial","volume":"40","author":"Mayne","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.diabres.2025.112204_b0805","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1210\/en.2013-1920","article-title":"Prevention of obesity-induced renal injury in male mice by DPP4 inhibition","volume":"155","author":"Nistala","year":"2014","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.diabres.2025.112204_b0810","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12933-025-02707-7","article-title":"Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF","volume":"24","author":"Luo","year":"2025","journal-title":"Cardiovasc Diabetol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725002189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725002189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T04:50:00Z","timestamp":1778388600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725002189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":162,"alternative-id":["S0168822725002189"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112204","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic crosstalk and therapeutic interplay between diabetes and hyperuricemia","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112204"}}